Drugs / DENVax
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT03342898 | Feb → May 2018 | dengue disease | Takeda | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2025-11-03 | Takeda | Results New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization takeda.com ↗
These data, including an exploratory analysis of a booster dose, confirm the favorable benefit and risk profile of QDENGA and that the two-dose regimen provides sustained protection against dengue. |
| 2023-10-03 | Takeda | Regulatory Takeda’s Dengue Vaccine Recommended by World Health Organization Advisory Group for Introduction in High Dengue Burden and Transmission Areas in Children Ages Six to 16 Years takeda.com ↗
Takeda ( TSE:4502/NYSE:TAK ) today announced that the World Health Organization’s (WHO) Strategic Advisory Group of Experts (SAGE) on Immunization shared recommendations for use of QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003). |
| 2022-11-22 | Takeda | Regulatory Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration takeda.com ↗
Takeda ( TSE:4502/NYSE:TAK ) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review of the Biologics License Application (BLA) for TAK-003, the company’s investigational dengue vaccine candidate. |
All press releases naming this drug 4 releases
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DENVax | “The vaccine tested in this study is TDV also known as TAK-003 (DENVax).” NCT03342898 ↗ |
| Known as | TAK-003 | “The vaccine tested in this study is TDV also known as TAK-003 (DENVax).” NCT03342898 ↗ |
| Known as | TDV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03342898 ↗ |
| Route | Subcutaneous | “TDV, 0.5 mL, injection, SC” NCT03342898 ↗ |